Clinical Trial Update: Effects of Maplirpacept (PF-07901801),Tafasitamab, and Lenalidomide in People With Relapsed or Refractory Diffuse Large B-cell Lymphoma [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 trial evaluating maplirpacept in combination with tafasitamab and lenalidomide for relapsed or refractory diffuse large B-cell lymphoma has been termi…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diffuse Large B-cell Lymphoma

Drugs mentioned

• Lenalidomide (lenalidomide)
• Maplirpacept (PF-07901801)
• tafasitamab (tafasitamab)

Snippet

Sponsor: Pfizer | Conditions: Diffuse Large B-Cell Lymphoma | Phase 1, Phase 2 | Status: TERMINATED | Results posted: 2025-09-05